July 22, 2024
Allogeneic Stem Cell Transplantation Market

The Allogeneic Stem Cell Transplantation Market Is Estimated To Witness High Growth

The allogeneic stem cell transplantation market is estimated to be valued at US$ 3.9 Billion In 2023 and is expected to exhibit a CAGR of 7.9% over the forecast period 2023 – 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Allogeneic stem cell transplantation involves transplanting stem cells from a donor into a patient. It is primarily used for treating cancers like leukemia, lymphoma and multiple myeloma. The stem cells can come from bone marrow, peripheral blood or umbilical cord blood. This type of transplantation restores stem cells that are destroyed by high doses of chemotherapy or radiation therapy given to destroy cancer cells in the patient’s body.

Market Dynamics:

Increasing prevalence of various types of cancers globally is expected to drive the growth of allogeneic stem cell transplantation market. According to the National Cancer Institute, in 2023, around 1.9 million new cancer cases are expected to be diagnosed in the US. In addition, the strong research pipeline for developing new applications of allogeneic stem cells in oncology and other therapeutic areas is also anticipated to fuel the market growth. Majority of clinical trials are focused on investigating the efficacy of stem cells in treatment of autoimmune diseases, cardiovascular diseases, neurological disorders, etc. Moreover, rising awareness about stem cells and their therapeutic benefits among patients and physicians have further propelled the adoption of allogeneic stem cell therapy. However, high treatment costs associated with allogeneic stem cell transplantation procedures might hamper the market growth in cost-sensitive regions.

Segment Analysis

The global Allogeneic Stem Cell Transplantation Market can be segmented based on products, therapies, ends users and applications. Based on product type, the market is segmented into stem cell sources, stem cell, tissue processing systems, cryopreservation systems and others. Stem cell sources sub segment currently dominates the market due to increasing cases of leukemia and blood cancer requiring stem cell transplantation procedures.

PEST Analysis

Political: Governments across the globe are supporting the development of stem cell based therapies by providing funding to relevant research projects. This is expected to boost the adoption of allogeneic stem cell transplantation procedures.
Economic: Favorable reimbursement policies for expensive stem cell transplantation procedures in developed countries is fueling the market growth.
Social: Increasing public awareness about potential life-saving applications of stem cells is positively impacting the market.
Technological: Significant advances in stem cell culture and cryopreservation techniques have improved the efficacy and safety of allogeneic stem cell transplantation therapies.

Key Takeaways

The global allogeneic stem cell transplantation market is expected to witness high growth, exhibiting a CAGR of 7.9% over the forecast period, due to increasing prevalence of blood cancer worldwide. The market was valued at US$ 3.9 Billion In 2023.

Regional analysis: North America accounted for the largest share in the global market in 2023 due to rising cancer incidence and supportive regulatory environment for stem cell based therapies in the region. Asia Pacific is expected to grow at the fastest pace during the forecast period.

Key players operating in the allogeneic stem cell transplantation market are Celgene Corporation, Mesoblast Ltd., Pluristem Therapeutics Inc., MEDIPOST Co., Ltd., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Cellular Biomedicine Group, Inc., Biosolution Co., Ltd., StemCell Technologies Inc., Caladrius Biosciences, Inc., TiGenix N.V., ViaCord, Vericel Corporation, Regen Biopharma Inc., Gamida Cell Ltd., Histogenics Corporation, BrainStorm Cell Therapeutics Inc., Lineage Cell Therapeutics, Inc.

1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it